Zika Virus Testing Market - Growth, Trends, and Forecast (2020 - 2025)
|発行||Mordor Intelligence LLP||商品コード||659355|
|出版日||ページ情報||英文 120 Pages
|ジカウイルス検査の世界市場：診断試験のタイプ、エンドユーザー、地理別の成長率、動向および予測 Zika Virus Testing Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日: 2020年02月01日||ページ情報: 英文 120 Pages||
Zika virus (ZIKV) infection has been known to be endemic in Africa and Southeast Asia. The consequent viral spread over the Pacific region led to an outbreak in the developed and emerging countries, worldwide. According to the World Health Organization (WHO), about 84 countries/territories are or have been previously infected by ZIKV transmission. There have been major outbreaks of Zika virus infection in Asia-Pacific (particularly India) and South American countries. As per the Centers for Disease Control and Prevention, Mexico, South America, Central, and Sub-Saharan African countries, and several countries in Southeast Asia are the major countries at risk for the growth of Zika virus infection. Thus, the rising prevalence of Zika virus infection is one of the primary factors driving the growth of the market studied, over the forecast period.
The other prominent drivers of the market studied are increasing R&D by biopharmaceutical companies, and technological advancements in diagnostic tests.
Serologic Test Segment is Expected to Show Better Growth in the Forecast Years
The Zika Virus Testing market has been segmented based on test type and end-user. The test type is further segmented into Molecular Test and Serologic Test. The serologic test is expected to grow due to their increased preference as they can detect acute as well as late-stage zika virus infection. In addition, emerging rapid detection serological diagnostics offer shorter turnaround time as well as the differential diagnosis of Zika against other flaviviruses. Furthermore, zika in early pregnancy increases risk of birth defects. According to the CDC, birth defects cases were reported in a higher proportion of babies whose mothers were infected with the zika virus during the first trimester of pregnancy. The virus can be transmitted from an infected pregnant woman to a fetus and causes microcephaly and other severe brain anomalies. This has prompted the testing of pregnant women for the Zika virus, further fueling the growth of the market.
North America Dominates the Market and is Expected to Follow the Same Trend Over the Forecast Period
North America is expected to dominate the market studied. The growth can be attributed to the rising awareness of the advantages of testing kits. The government organizations, such as the Centers for Disease Control and Prevention (CDC), Pan American Health Organization (PAHO), etc., have been mainly involved in the prevention of Zika virus infection. As per the CDC, About 2 in 20 (10%) babies of women with confirmed Zika virus infection during pregnancy in US states and about 1 in 20 (5%) in US territories had Zika-associated birth defects. The CDC has received funding, to combat the zika outbreak across several territories. In addition, the developed healthcare infrastructure, along with rapid technological advancements by several biopharmaceutical companies in the testing of the zika virus is expected to positively impact the market.
The global players in the Zika Virus Testing market are Abbott Laboratories, Altona Diagnostics GmbH, Chembio Diagnostic Systems Inc., ELITechGroup, F. Hoffmann-La Roche Ltd, Genekam, Luminex Corporation, Novacyt Group, Quest Diagnostics and Siemens AG.